OBJECTIVES: To estimate the daily cost of intensive care unit (ICU) stay in France using a microcosting methodology. METHODS: A multicentre prospective cost analysis was carried out among 23 French ICUs randomly selected from the French National Hospital database stratified by hospital category (regional, university and private non profit). Each ICU enrolled 5 adult patients admitted from May to October, 2009, selected at random, with a simplified acute physiology score (SAPS)II ≥ 15 and with at least 24 hours of ICU stay. All healthcare resources used by each patient over a 24-hour period were recorded, as well as the time spent by all hospital staff involved in the patient’s management. All resources identified were valued from a hospital perspective (reference year 2009) based on cost data provided by each participating hospital. All healthcare resources used by each patient over a 24-hour period were recorded, as well as the time spent by all hospital staff involved in the patient’s management. All resources identified were valued from a hospital perspective (reference year 2009) based on cost data provided by each participating hospital.

RESULTS: A total of 104 patients were enrolled by 21 ICUs (14 polyvalent, 3 surgical and 4 medical) were included. The mean age of patients was 62.3 years (SD 14.9); 64% were male; 86% were mechanically ventilated. Staff costs contributed the most to hospital costs (62%); SOFA score was the main component of hospital costs (43%). Staff time represented the largest component of this cost (43%) followed by overheads, capital, hotel and nutrition assigned to the ICU (22%). Medications and consumables used accounted for 18.6% of the total cost. The majority of the cost (59%) was patient-dependent. The two main patient-dependent factors associated with significantly higher costs were: a high SOFA score and being on continuous mechanical ventilation.

CONCLUSIONS: This first French microcosting study in ICU demonstrated that the cost per day of ICU care is substantially dependent on the patient’s medical profile and mainly driven by labour components.

PHP76
THE LACK OF BIA METHODOLOGY IN THE CZECH REPUBLIC LEADS TO INAPPROPRIATE PUBLIC HEALTH INSURANCE BUDGETING
Hasišová M1, Zizalková J2, Filipa L1, Balogová K2
1 Ministry of Health of the Czech Republic, Prague, Czech Republic
2General Insurance Company of the Czech Republic, Prague, Czech Republic

OBJECTIVES: Budget impact analysis (BIA) is a tool used to predict and understand the potential financial impact of introducing a new health care intervention into a health care system that has finite financial resources. Czech laws only prescribe duty to attach BIAs to the applications for new drug reimbursements without specifying guidelines how to prepare BIA. We analyzed the differences between the BIA in the applications and the real expenditures of the public health insurance.

METHODS: We have selected 3 applications of new drugs (tromipol, lenalidomid, bevacizumab) submitted in year 2009 (or an established drug in new indication) and compared submitted BIA estimates for year 2010 with the real expenditures in the same year. We also compared the methods in the submitted BIAs with the Impact Analysis Guidelines published by Patented Medicine Prices Review Board (Canadian National Drug Reimbursement Authority) to identify potential reasons of differences.

RESULTS: We found differences in the predicted number of patients, average cost of drug application and total impact on the public health insurance.

CONCLUSIONS: The comparison with standard guidelines identified the key areas to be addressed in the future Czech legislative to improve the quality of submitted BIAs. The inaccuracies were mainly caused due to: a) Lack of data sources and their transparency; b) Inaccurate or misapplied assumptions; c) Inappropriate choice of comparators, and d) Overall quality, e.g. false interpretation of referenced studies conclusions.

PHP77
EXPLORING DIFFERENT HRQOL MEASURES AS PREDICTORS OF FUTURE HEALTH CARE EXPENDITURES
Gatwood J, Erickson S
University of Michigan, Ann Arbor, MI, USA

OBJECTIVES: To assess the relative ability of several health-related quality of life (HRQOL) measures to predict future health care expenditures. METHODS: Data from the Medical Expenditure Panel Survey (MEPS) for years 2003 (Panel 4, Round 2) and 2004 were used for study purposes and weighted in order to gain a population-representative sample. The combined use of the SF-12 MCS and PCS measures as need variables in the Model of Health Services Use performed better than the other HRQOL measures in the MEPS dataset in predicting future health care expenditures.

OBJECTIVES: On January 1, 2011, the rapid benefit assessment (RBA) as basis for ceniral price regulations was introduced for new drugs in Germany. It requires the characterization of all manufacturers’ value propositions. Based on the broad spectrum of the western world (Europe, North America, Israel). Where needed informal stakeholder interviews were used to supplement lacking information. The information was extracted and evaluated based on 10 characteristics obtained from the “ISFPR Prioritized Good Research Practice for Budget Impact Analysis” (Maukopf et al. 2007). RESULTS: All of the investigated countries except for Germany, Scotland and Norway consider the direct medical budget impact of new pharmaceuticals in their reimbursement decision making. In Germany, only the maximum annual direct interventional price for a drug is set. From a payer’s perspective the drug’s impact on the change in medical resource consumption is analyzed as part of the pharmacoeconomic and comparative effectiveness analyses. 8 countries demand a self-contained BIA complementary to the broader health economic evaluation, while 3 countries deal with financial consequences as part of the economic evaluation. In all countries except for Germany economic consequences for the healthcare budget have to be presented for at least 2-5 years on an annual basis to capture medium term to long term savings and expenditures associated with changes in the medical resource utilization following a drug’s availability in the market. CONCLUSIONS: All investigated countries except Germany consider changes in the resource consumption and their financial consequences (even for a medium term period) for decision making.

PHP79
WHAT ARE THE RESEARCH PRIORITIES IN THE SPANISH NATIONAL HEALTH SYSTEM? A COMPARISON OF ECONOMIC EVALUATIONS OF HEALTH CARE INTERVENTIONS AND PUBLIC-FUNDED RESEARCH
Catalá-López F1, García-Alba A2, Génova-Maleras R1, Álvarez-Martin F1
Morant-Cinestà C1, Pérez S2
1Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain
2Catálogo de Información sobre el Impacto de la Investigación y la Enseñanza. Departamento de Sanidad, Educación y Deporte, Madrid, Spain

OBJECTIVES: The efficient use of resources requires explicit criteria for setting health research prioritization. We assessed whether economic evaluations of healthcare interventions are directed to priority diseases in the allocation of public-fund sponsored research in the Spanish National Health System. METHODS: We analyzed data from a systematic review of economic evaluations performed in Spain (period 1983-2008). Reports were grouped according to the source of funding. We included a representative sample of public funds allocated to research projects (2006/2007 calls of the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation). Both economic evaluations and research projects were classified according to the main disease causes, following the classification proposed by the World Health Organization in its Global Burden of Disease study. We calculated Spearman correlation coefficients (r) between the public funds and economic evaluations. RESULTS: A total of 1410 research projects (equal to €12.6 million) and 477 economic evaluations were identified and could be categorized in 20 groups and 40 specific causes of diseases. For major groups (n = 20), the associations were: total economic evaluations (r = 0.80, p < 0.001), economic evaluations funded by for-profit organizations (r = 0.77, p < 0.001) and those funded by nonprofit organizations (r = 0.85, p < 0.001). For specific disease-causes (n = 40), total economic evaluations (r = 0.52, p < 0.001), economic evaluations funded by for-profit organizations (r = 0.72, p < 0.001) and those funded by nonprofit organizations (r = 0.51, p < 0.001). CONCLUSIONS: The distribution of priorities is similar between economic evaluations and public research funds allocated to specific diseases. However, the optimal level of these distributions could be determined with additional analyses on the impact of research results in reducing the burden of disease in the population.

PHP80
A CHEAP MEDICINE IS NOT THE SAME AS A GENERIC MEDICINE: THE BELGIAN CASE
Dylat P1, Vulto A2, Simoons S2
1ULB-Leuven, Leuven, Vlaams Brabant, Belgium, 2Erasmus University Medical center, Hospital Pharmacy, Rotterdam, The Netherlands

OBJECTIVES: The aim of this study is to describe the experience with the Belgian policy that obliges physicians to prescribe minimum quota of cheap medicines and to document the outcomes of this policy using publicly available data. METHODS: Data were obtained from yearly feedback reports of the policy on the website of the Belgian third-party payer (RIZIV/INAMI) which were sent to all physicians. Data were derived from Farmarant, a database where all data of prescriptions of reimbursed medicines from all physicians in Belgium are collected. RESULTS: All groups of general practitioners, specialists and dentists reached their minimum purchase percentages every year from 2006 until 2009. The percentage of cheap medicines (in DDD) increased from 22.9% in January 2005 to 44.2% of all prescribed medicines in ambulatory care in December 2009. The percentage of generic medicines increased from 5.7% in January 2004 to 24.0% by January 2008 in ambulatory care in 2008. When a physician prescribed a cheap medicine, this was an original medicine whose price had dropped to the reference price level in 41.5% of cases in August 2009. CONCLUSIONS: The policy of prescribing quota for cheap medicines was not only associated with increased prescribing of generic medicines during 2004-2008, but also increased prescribing of original medicines whose price had dropped to the reference price level. The potential for prescribing generic medicines has not